FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
- Is Lear, Back From Bankruptcy, a Buy?
- Sanofi-Aventis Falling Off a Patent Cliff?
- Cramer: Your Thanksgiving Week Game Plan
- Cramer: Next Week Should Define Rest of ‘09
- Mad Money: Mad Mail: Buy RIM or Apple?
- Lightning Round: Cisco Systems, Citigroup, Baidu.com and More
- Lightning Round OT: Martek Biosciences, Valmont Industries and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
It’s all about management and its ability to execute, Cramer told viewers during Wednesday’s Mad Money. That’s what separates strong companies from the weak in this market. So forget about sector-based ETFs – investors should be buying CEOs.
So who are these top-performing firms? How about Research in Motion [RIMM
Loading...
()
], Apple [AAPL
Loading...
()
] and newly resurgent Palm [PALM
Loading...
()
]. They’re making the products that people want. Rivals Nokia[NOK
Loading...
()
] and Motorola [MOT
Loading...
()
], who missed Q4 expectations Tuesday and suspended its dividend, do not.
Look at Clorox [CLX
Loading...
()
] and Colgate-Palmolive [CL
Loading...
()
], too. Both companies recently delivered great quarters, thanks to solid execution, and they look set to emerge from this recession stronger than their competitors. Kraft Foods and Sara Lee sell many of the same products, but returned none of the same results. Who’s to blame? Cramer said management.
The same trend is also taking place in the banks. Goldman Sachs [GS
Loading...
()
] is ready to pay off its TARP debt, while Citigroup [C
Loading...
()
] needs more money. So does Bank of America [BAC
Loading...
()
]. Morgan Stanley [MS
Loading...
()
] has a new business model – pure brokerage, while UBS [UBS
Loading...
()
], Cramer said, has no business model at all. That’s why Goldman and Morgan were up big Wednesday.
Biotech’s no different either. Abbott Labs [ABT
Loading...
()
] is returning double-digit growth as a result of innovation. The company released a new heart stent, and an anti-inflammatory franchise, Humira, is doing well. But what does Pfizer [PFE
Loading...
()
] do in order to grow? Buy Wyeth [WYE
Loading...
()
]. And let’s not forget that J&J cut its dividend in half, back on Jan. 26, in an attempt to raise money for the deal.
The good-versus-bad execution theme can be seen across the market – in oil, personal computers, manufacturing, any of the aforementioned sectors. And these poor performers are the reason we lost 122 Dow points today. So Cramer’s recommendation was to avoid these losers and stick with the winners who can execute. It’s a much better investment strategy than “playing it safe” with a broad-based exchange-trade fund.
Cramer's charitable trust owns Abbott Labs, Goldman Sachs and Morgan Stanley.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes